

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,381	05/16/2005	Douglas Wade Beight	X16014	3880
25885 ELILILLY &	7590 02/27/200 COMPANY	8	EXAM	INER
PATENT DIVISION			RAHMANI, NILOOFAR	
P.O. BOX 628 INDIANAPOI	8 .IS, IN 46206-6288		ART UNIT PAPER NUMBER 1625	
11011111101	30,111 10200 0200			
			NOTIFICATION DATE	DELIVERY MODE
			02/27/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

patents@lilly.com

Application No. Applicant(s)

Interview Summary	10/535,381	BEIGHT ET AL.	
merview dummary	Examiner	Art Unit	
	NILOOFAR RAHMANI	1625	
All participants (applicant, applicant's representative, PTO	personnel):		
(1) <u>NILOOFAR RAHMANI</u> .	(3)		
(2) <u>Danica Hotettler</u> .	(4)		
Date of Interview: 15 February 2008.			
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2	2) applicant's representative	e]	
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e)⊠ No.		
Claim(s) discussed: <u>14 and 15</u> .			
Identification of prior art discussed: <u>NONE</u> .			
Agreement with respect to the claims f) was reached. g	ı)∏ was not reached. h)⊠ N	I/A.	
Substance of Interview including description of the general reached, or any other comments: "JClaims 15-16 are meth under 112, 1st enablement. However, the attorney agreed will submit the case law (Yamanouchi Pharmaceutical comments of the 100 or cut out some compounds to overcome the 103 (A fuller description, if necessary, and a copy of the amend allowable, if available, must be attached. Also, where no callowable is available, a summary thereof must be attached. The comments of the 100 or the 100 o	od of treatment claims and sh to delete these claims to furth position vs. Danbury Pharmac (a) rejection. Iments which the examiner ag opt of the amendments that w 1.) CTION MUST INCLUDE THE last Office action has already OF ONE MONTH OR THIRT ERVIEW SUMMARY FORM,	could have been per prosecution. 2 cal INC. [231f.3] reed would rend could render the SUBSTANCE (been filed, APP (DAYS FROM 1 WHICHEVER IS	rejected Applicant d1339,1345, From the claims claims OF THE LICANT IS HIS LATER, TO
Examiner Note: You must sign this form unless it is an	/D. Margaret Seaman/ Primary Examiner, Art Unit 16 Examiner's signature, if requi		

Attachment to a signed Office action.
U.S. Patent and Trademark Office
PTOL-413 (Rev. 04-03) Interview Summary Paper No. 20080215